Company-wide revenue
Reported revenue in 2021 ¥414.42M Reported revenue in 2025 ¥387.62M
- growth amount
- −¥26.8M
- growth annualized
- -1.7%
- growth total
- -6.5%
Japanese company profile · 4576
English company name recorded in Japan's EDINET filer data.
Original Japanese company name: 株式会社デ・ウエスタン・セラピテクス研究所
Name follows the English name recorded in EDINET filer data. English company name source
FY2025 · fiscal year ended December 2025Latest filing date: 2026-03-23What does this company do?
In its FY2025 public filing, D.Western Therapeutics Institute, Inc. reports Drug Discovery. The page shows business-level revenue and profit where the source disclosures support comparison.
D.Western Therapeutics Institute, Inc.'s largest reported business by revenue in FY2025 was Drug Discovery.
FY2025 · fiscal year ended December 2025 · View original filing ↗ The source document may be in Japanese.
JGAAP · Consolidated company-wide
Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab
Business structure
| Business | Sales | Share of company sales | Operating profit | Margin |
|---|---|---|---|---|
| Drug Discovery | ¥387.62M ↗ | — | −¥619.87M ↗ | -159.9% |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended December 2025. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.
Company revenue
Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.
Reported Sales by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Drug Discovery | ¥414.42M | ¥448.1M | ¥428.36M | ¥471.58M | ¥387.62M |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
Reported revenue in 2021 ¥414.42M Reported revenue in 2025 ¥387.62M
This describes a reported period; it is not a forecast.
What has changed?
A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.
Source
These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.
Source
FY2025 · fiscal year ended December 2025
The source document may be in Japanese.
Filing ID: S100XS4G
View original filing ↗